A Phase 2, Open-Label, Non-Comparative, Multi-Center Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Trial Profile

A Phase 2, Open-Label, Non-Comparative, Multi-Center Extension Study to Evaluate the Long-term Safety and Efficacy of ASP015K in Subjects Previously Enrolled in a Phase 2 ASP015K Rheumatoid Arthritis Study

Completed
Phase of Trial: Phase II

Latest Information Update: 22 Aug 2016

At a glance

  • Drugs Peficitinib (Primary)
  • Indications Rheumatoid arthritis
  • Focus Adverse reactions
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 08 Apr 2016 Status changed from active, no longer recruiting to completed, according to European Clinical Trials Database record.
    • 24 Sep 2014 Planned End Date changed from 1 Feb 2016 to 1 Mar 2016 as reported by ClinicalTrials.gov record.
    • 03 Mar 2014 Planned End Date changed from 1 Dec 2016 to 1 Feb 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top